Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:170-175

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujihara, C. K.
Right arrow Articles by Zatz, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujihara, C. K.
Right arrow Articles by Zatz, R.
Related Collections
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2001;37:170.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Mycophenolate Mofetil Reduces Renal Injury in the Chronic Nitric Oxide Synthase Inhibition Model

Clarice Kazue Fujihara; Denise Maria Avancini Costa Malheiros; Irene de Lourdes Noronha; Gilberto De Nucci; Roberto Zatz

From the Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.

Correspondence to Roberto Zatz, MD, PhD, Laboratório de Fisiopatologia Renal, Av. Dr. Arnaldo, 455, 3-s/3342, 01246–903, São Paulo, SP, Brazil. E-mail rzatz{at}usp.br

Abstract—We and others have recently shown that mycophenolate mofetil (MMF) reduces renal inflammation and glomerular and interstitial injury in the 5/6 renal ablation model. In the present study, we investigated whether MMF limits renal injury in a model of chronic nitric oxide (NO) inhibition associated with a high-salt diet and characterized by progressive systemic hypertension, albuminuria, glomerular sclerosis and ischemia, interstitial expansion, and progressive macrophage infiltration. Adult male Münich-Wistar rats were distributed among 3 groups: HS, rats receiving a high-salt diet (3.2% Na); HS+N, HS rats orally treated with the NO inhibitor N{omega}-nitro-L-arginine methyl ester (L-NAME), 25 mg · kg-1 · d-1; and HS+N+MMF, HS+N rats orally treated with MMF, 10 mg · kg-1 · d-1. Renal hemodynamics were studied after 15 days of treatment; histological and immunohistochemical studies were conducted after 30 days of treatment. MMF treatment did not reverse the hemodynamic alterations characteristic of this model. Renal injury in the HS+N group was associated with macrophage and lymphocyte infiltration. Treatment with MMF reduced glomerular and interstitial injury and limited macrophage and lymphocyte infiltration. These results suggest that renal inflammation is a strong independent factor in the pathogenesis of the nephropathy associated with the HS+N model.


Key Words: mycophenolate mofetil • nitric oxide • renal inflammation • renal hemodynamics




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
E. Tapia, D. J. Sanchez-Gonzalez, O. N. Medina-Campos, V. Soto, C. Avila-Casado, C. M. Martinez-Martinez, R. J. Johnson, B. Rodriguez-Iturbe, J. Pedraza-Chaverri, M. Franco, et al.
Treatment with pyrrolidine dithiocarbamate improves proteinuria, oxidative stress, and glomerular hypertension in overload proteinuria
Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1431 - F1439.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. D. Crowley, C. W. Frey, S. K. Gould, R. Griffiths, P. Ruiz, J. L. Burchette, D. N. Howell, N. Makhanova, M. Yan, H.-S. Kim, et al.
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension
Am J Physiol Renal Physiol, August 1, 2008; 295(2): F515 - F524.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. L. Graciano, A. Nishiyama, K. Jackson, D. M. Seth, R. M. Ortiz, M. C. Prieto-Carrasquero, H. Kobori, and L. G. Navar
Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F161 - F169.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. L. Graciano, C. R. Mouton, M. E. Patterson, D. M. Seth, J. J. Mullins, and K. D. Mitchell
Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension
Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1858 - F1866.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
C. K. Fujihara, C. R. Sena, D. M. A. C. Malheiros, A. L. Mattar, and R. Zatz
Short-term nitric oxide inhibition induces progressive nephropathy after regression of initial renal injury
Am J Physiol Renal Physiol, March 1, 2006; 290(3): F632 - F640.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Mauro Vieira Jr, E. Mantovani, L. Tavares Rodrigues, H. Delle, I. L. Noronha, C. K. Fujihara, and R. Zatz
Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1582 - 1591.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. L. Graciano, R. d. C. Cavaglieri, H. Delle, W. V. Dominguez, D. E. Casarini, D. M. A. C. Malheiros, and I. L. Noronha
Intrarenal Renin-Angiotensin System Is Upregulated in Experimental Model of Progressive Renal Disease Induced by Chronic Inhibition of Nitric Oxide Synthesis
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1805 - 1815.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. C. Campbell
The Renin-Angiotensin System: A 21st Century Perspective
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1963 - 1964.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Zatz, I. L. Noronha, and C. K. Fujihara
Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies
Am J Physiol Renal Physiol, December 1, 2002; 283(6): F1167 - F1175.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. Y. Karim, P. Alba, M.-J. Cuadrado, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents
Rheumatology, August 1, 2002; 41(8): 876 - 882.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
I. L. Noronha, C. K. Fujihara, and R. Zatz
The inflammatory component in progressive renal disease--are interventions possible?
Nephrol. Dial. Transplant., March 1, 2002; 17(3): 363 - 368.
[Full Text] [PDF]